Skip to main content
Journal cover image

Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Publication ,  Journal Article
Samman Tahhan, A; Hayek, SS; Sandesara, P; Hajjari, J; Hammadah, M; O'Neal, WT; Kelli, HM; Alkhoder, A; Ghasemzadeh, N; Ko, Y-A; Aida, H ...
Published in: Atherosclerosis
September 2017

BACKGROUND AND AIMS: Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study. METHODS: SuPAR levels were measured in 5810 patients (mean age 63 years, 63% male, 77% with obstructive coronary artery disease [CAD]) undergoing cardiac catheterization. The presence of PAD (n = 967, 17%) was classified as carotid (36%), lower/upper extremities (30%), aortic (15%) and multisite disease (19%). Multivariable logistic and Cox regression models were used to determine independent predictors of prevalent PAD and outcomes including all-cause death, cardiovascular death and PAD-related events after adjustment for age, gender, race, body mass index, smoking, diabetes, hypertension, hyperlipidemia, renal function, heart failure history, and obstructive CAD. RESULTS: Plasma suPAR levels were 22.5% (p < 0.001) higher in patients with PAD compared to those without PAD. Plasma suPAR was higher in patients with more extensive PAD (≥2 compared to single site) p < 0.001. After multivariable adjustment, suPAR was associated with prevalent PAD; odds ratio (OR) for highest compared to lowest tertile of 2.0, 95% CI (1.6-2.5) p < 0.001. In Cox survival analyses adjusted for clinical characteristics and medication regimen, suPAR (in the highest vs. lowest tertile) remained an independent predictor of all-cause death [HR 3.1, 95% CI (1.9-5.3)], cardiovascular death [HR 3.5, 95% CI (1.8-7.0)] and PAD-related events [HR = 1.8, 95% CI (1.3-2.6) p < 0.001 for all]. CONCLUSIONS: Plasma suPAR level is predictive of prevalent PAD and of incident cardiovascular and PAD-related events. Whether SuPAR measurement can help screen, risk stratify, or monitor therapeutic responses in PAD requires further investigation.

Duke Scholars

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

September 2017

Volume

264

Start / End Page

108 / 114

Location

Ireland

Related Subject Headings

  • Up-Regulation
  • Time Factors
  • Risk Factors
  • Receptors, Urokinase Plasminogen Activator
  • Proportional Hazards Models
  • Prognosis
  • Prevalence
  • Peripheral Arterial Disease
  • Odds Ratio
  • Multivariate Analysis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Samman Tahhan, A., Hayek, S. S., Sandesara, P., Hajjari, J., Hammadah, M., O’Neal, W. T., … Quyyumi, A. (2017). Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis, 264, 108–114. https://doi.org/10.1016/j.atherosclerosis.2017.06.019
Samman Tahhan, Ayman, Salim S. Hayek, Pratik Sandesara, Jamal Hajjari, Muhammad Hammadah, Wesley T. O’Neal, Heval M. Kelli, et al. “Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.Atherosclerosis 264 (September 2017): 108–14. https://doi.org/10.1016/j.atherosclerosis.2017.06.019.
Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O’Neal WT, et al. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis. 2017 Sep;264:108–14.
Samman Tahhan, Ayman, et al. “Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.Atherosclerosis, vol. 264, Sept. 2017, pp. 108–14. Pubmed, doi:10.1016/j.atherosclerosis.2017.06.019.
Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O’Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko Y-A, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, Sperling L, Quyyumi A. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis. 2017 Sep;264:108–114.
Journal cover image

Published In

Atherosclerosis

DOI

EISSN

1879-1484

Publication Date

September 2017

Volume

264

Start / End Page

108 / 114

Location

Ireland

Related Subject Headings

  • Up-Regulation
  • Time Factors
  • Risk Factors
  • Receptors, Urokinase Plasminogen Activator
  • Proportional Hazards Models
  • Prognosis
  • Prevalence
  • Peripheral Arterial Disease
  • Odds Ratio
  • Multivariate Analysis